CO2022018053A2 - Anticuerpos anti-pd-1 y proteínas de fusión - Google Patents

Anticuerpos anti-pd-1 y proteínas de fusión

Info

Publication number
CO2022018053A2
CO2022018053A2 CONC2022/0018053A CO2022018053A CO2022018053A2 CO 2022018053 A2 CO2022018053 A2 CO 2022018053A2 CO 2022018053 A CO2022018053 A CO 2022018053A CO 2022018053 A2 CO2022018053 A2 CO 2022018053A2
Authority
CO
Colombia
Prior art keywords
antibodies
methods
fusion proteins
same
binding
Prior art date
Application number
CONC2022/0018053A
Other languages
English (en)
Spanish (es)
Inventor
Dan Lu
Zhanna Polonskaya
Tzu-Pei Chang
Stella A Martomo
Jeegar Patel
Faical Miyara
Original Assignee
Kadmon Corp Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kadmon Corp Llc filed Critical Kadmon Corp Llc
Publication of CO2022018053A2 publication Critical patent/CO2022018053A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CONC2022/0018053A 2020-06-23 2022-12-13 Anticuerpos anti-pd-1 y proteínas de fusión CO2022018053A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043114P 2020-06-23 2020-06-23
US202063111459P 2020-11-09 2020-11-09
PCT/US2021/038740 WO2021262880A2 (en) 2020-06-23 2021-06-23 Anti-pd-1 antibodies and fusion proteins

Publications (1)

Publication Number Publication Date
CO2022018053A2 true CO2022018053A2 (es) 2022-12-20

Family

ID=79282816

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0018053A CO2022018053A2 (es) 2020-06-23 2022-12-13 Anticuerpos anti-pd-1 y proteínas de fusión

Country Status (13)

Country Link
US (4) US20230416363A1 (enExample)
EP (3) EP4729531A3 (enExample)
JP (2) JP7644151B2 (enExample)
KR (1) KR20230027267A (enExample)
CN (1) CN116194471A (enExample)
AU (1) AU2021296437A1 (enExample)
BR (1) BR112022025632A2 (enExample)
CA (1) CA3184746A1 (enExample)
CO (1) CO2022018053A2 (enExample)
IL (1) IL299238A (enExample)
MX (1) MX2022016588A (enExample)
PH (1) PH12022500029A1 (enExample)
WO (1) WO2021262880A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116194471A (zh) 2020-06-23 2023-05-30 卡德门企业有限公司 抗pd-1抗体和融合蛋白
CN116333155A (zh) * 2023-03-09 2023-06-27 杭州美赛生物医药科技有限公司 靶向pd-1和vegf的双功能抑制剂
WO2025048616A1 (ko) * 2023-08-31 2025-03-06 주식회사 지아이셀 Il-2 단백질 및 il-15 단백질의 키메라 단백질 또는 변이체, 이를 포함하는 융합단백질, 및 이를 발현하는 유전자 조작된 세포
WO2025217310A1 (en) * 2024-04-10 2025-10-16 Prolynx Llc Pegylated il- 15 receptor alpha cytokines
WO2026158432A1 (zh) * 2025-01-24 2026-07-30 江苏奥赛康生物医药有限公司 抗pd-1抗体-il-15前药的融合分子与化学治疗药物的组合及其应用
WO2026161860A1 (en) * 2025-01-27 2026-07-30 Kadmon Corporation, Llc Dosing of immunocytokines for cancer treatment

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
ATE329263T1 (de) * 1998-10-30 2006-06-15 Jonathan L Miller Regionen variabler schwerer ketten und variabler leichter ketten von antikörpern für humanes blutplättchen-glykoprotein ib alpha
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
GB0816461D0 (en) * 2008-09-09 2008-10-15 Univ Manchester Biomass
WO2011130417A2 (en) * 2010-04-15 2011-10-20 Amgen Inc. HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
JP6251570B2 (ja) * 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
LT2748201T (lt) * 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
HK1200850A1 (en) * 2011-09-23 2015-08-14 罗氏格黎卡特股份公司 Bispecific anti-egfr/anti igf-1r antibodies
WO2014023709A1 (en) * 2012-08-09 2014-02-13 Roche Glycart Ag Asgpr antibodies and uses thereof
EP3027649B1 (en) * 2013-08-01 2020-04-01 F.Hoffmann-La Roche Ag Tnfa-il-17 bispecific antibodies
US8945560B1 (en) * 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
LT3094351T (lt) * 2014-01-15 2022-04-11 Kadmon Corporation, Llc Imunitetą moduliuojantys agentai
JP6996979B2 (ja) * 2015-03-31 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 三量体ｔｎｆファミリーリガンドを含む抗原結合分子
AU2016326575A1 (en) * 2015-09-25 2018-04-12 Altor Bioscience Corporation Interleukin-15 superagonist significantly enhances graft-versus-tumor activity
EP3455254B1 (en) * 2016-05-11 2021-07-07 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
KR102048476B1 (ko) * 2016-08-05 2019-11-26 주식회사 와이바이오로직스 프로그램화된 세포 사멸 단백질(pd-1)에 대한 신규 항체 및 이의 용도
MX2019004327A (es) 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
LT3535298T (lt) * 2016-11-02 2021-12-27 Jounce Therapeutics, Inc. Antikūnai prieš pd-1 ir jų panaudojimas
AU2018291497A1 (en) * 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
GB201803745D0 (en) * 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
CA3097593A1 (en) * 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
CA3116188A1 (en) 2018-10-12 2020-04-16 Xencor, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
CN116194471A (zh) 2020-06-23 2023-05-30 卡德门企业有限公司 抗pd-1抗体和融合蛋白

Also Published As

Publication number Publication date
CA3184746A1 (en) 2021-12-30
EP4610275A3 (en) 2025-12-03
EP4168124A2 (en) 2023-04-26
US12612460B2 (en) 2026-04-28
JP7644151B2 (ja) 2025-03-11
IL299238A (en) 2023-02-01
US20250136693A1 (en) 2025-05-01
US20260176362A1 (en) 2026-06-25
US20230416363A1 (en) 2023-12-28
JP2025091418A (ja) 2025-06-18
PH12022500029A1 (en) 2024-04-22
MX2022016588A (es) 2023-03-15
WO2021262880A2 (en) 2021-12-30
AU2021296437A1 (en) 2023-02-23
BR112022025632A2 (pt) 2023-01-17
US20260217831A1 (en) 2026-07-30
KR20230027267A (ko) 2023-02-27
EP4729531A2 (en) 2026-04-22
EP4610275A2 (en) 2025-09-03
WO2021262880A3 (en) 2022-02-17
EP4729531A3 (en) 2026-07-15
CN116194471A (zh) 2023-05-30
EP4168124A4 (en) 2024-10-02
JP2023531920A (ja) 2023-07-26

Similar Documents

Publication Publication Date Title
BR112022025632A2 (pt) Anticorpos anti-pd-1 e proteínas de fusão
CO2021007956A2 (es) Anticuerpo humanizado anti-pd-1 humana
MX2025000370A (es) Anticuerpos anti-ctla4 y metodos para elaborarlos y usarlos
MX2018013548A (es) Proteinas de union biespecificas y usos de las mismas.
PE20190911A1 (es) Composiciones y anticuerpos anti-lag-3
PE20200867A1 (es) Conjugados que comprende una muteina de interleucina 21 y un anticuerpo anti-pd-1
MX2021013532A (es) Materiales y metodos para modular la inmunidad mediada por celulas t.
PE20181044A1 (es) Anticuerpos anti-pd-1 y composiciones
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
MX2017009535A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123.
BR112019008859A2 (pt) anticorpos direcionados contra a morte programada 1 (pd-1)
BR112018076281A2 (pt) imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo
BR112019008010A2 (pt) anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
MX2019013132A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
AR108779A1 (es) Anticuerpos
MX2020010913A (es) Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos.
MX2020012350A (es) Anticuerpos anti-cd63, conjugados y usos de estos.
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
MX2021010281A (es) Proteinas de enlace a antigenos que se enlazan al bcma.
UY37457A (es) Compuestos de anticuerpos acoplados de tirosina-tirosina cíclica como moduladores de receptores del neuropeptido y
PE20190371A1 (es) Anticuerpos de interferon beta y usos de los mismos
AR117327A1 (es) Anticuerpos anti-cd96 y métodos de uso de estos
MX2022014736A (es) Anticuerpos anti-cd200r1 y metodos de uso de estos.
ECSP22041860A (es) Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso
MX2023011788A (es) Anticuerpos contra ilt4, anticuerpo biespecifico anti-ilt4/pd-l1 y usos de los mismos.